Laboratory AI achieves ‘excellent to outstanding’ COVID rule-out accuracy

Researchers have demonstrated a machine learning model that can rule out COVID-19 in many emergency patients—and all the algorithm needs is data from routine ER blood tests.

Timothy Plante, MD, MHS, of the University of Vermont and colleagues describe their project in the Journal of Medical Internet Research.

The team trained the model on around 2,200 cases of COVID across 43 hospitals as confirmed by testing with reverse transcription polymerase chain reaction (PCR).

For negative controls, they used 10,000 pre-pandemic patients who were seen at the same hospitals.

For external validation, they used 23 hospitals with more than 1,000 PCR-confirmed cases and around 172,000 pre-pandemic negative controls.

To evaluate the model’s accuracy, Plante and colleagues used area under the receiver operating characteristic curve as well as sensitivity, specificity and negative predictive value.

Based on a risk score cutoff of 1.0 out of 100 in the external validation dataset, the model had sensitivity of 95.9% and specificity of 41.7%.

When the risk cutoff was bumped up to 2.0, the model achieved 92.6% sensitivity and 59.9% specificity.

Meanwhile, with the 2.0 cutoff, the negative predictive values were 99.9%, 98.6%, and 97% at disease prevalence rates of 1%, 10% and 20%, respectively.

“A machine learning model developed with multicenter clinical data integrating commonly collected ED laboratory data demonstrated high rule-out accuracy for COVID-19 status and might inform selective use of PCR-based testing,” the authors conclude.

They underscore that their model integrates commonly collected laboratory data and state that it “had a discrimination accuracy that can be classified as excellent to outstanding.”

The study is available in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”